Pharming Group Highlights Leniolisib Pediatric APDS Data at CIS 2026
Leiden, the Netherlands, May 7, 2026 Pharming Group N.V. announced a major scientific presence at the 2026 Annual Meeting...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Leiden, the Netherlands, May 7, 2026 Pharming Group N.V. announced a major scientific presence at the 2026 Annual Meeting...
CAMBRIDGE, Mass., May 6, 2026 Nona Biosciences, a global biotechnology company specializing in biotherapeutic discovery and AI-driven drug development...
BERLIN, Germany, and SAN FRANCISCO, Calif., May 6, 2026 Bayer has announced an agreement to fully acquire Perfuse Therapeutics...
SUZHOU, China, Feb. 15, 2026 — CStone Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Investigational...
SHANGHAI, Feb. 12, 2026 — AGCO Biomedical Technology Co., Ltd. announced that the U.S. Food and Drug Administration (FDA)...
Ingelheim, Germany | January 29, 2026 — Boehringer Ingelheim announced positive results from a 12-week Phase II clinical trial...
December 21, 2025 | Beijing, China — T-MAXIMUM Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has...
Paris, France, December 19, 2025 — Ipsen, a global biopharmaceutical company, announced an update on its pivotal Phase II...
Kiel, Germany, December 2, 2025 — Tiakis Biotech has announced that it has successfully completed the required preclinical data...
Toronto, December 1, 2025 — New clinical data from the Phase II ARCHER trial reveal that CardiolRx™, Cardiol Therapeutics’...
